Forteo Injection, Solution
NDC Package 0002-9678-01
Package Information
Forteo (teriparatide) injection is teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. This formulation utilizes a injection, solution delivery system. Marketed by Eli Lilly And Company, this product is identified by NDC 0002-9678 and is authorized under FDA application NDA021318.
Identification & Billing
- RxCUI: 1435115 - teriparatide 20 MCG/Dose in 28 Dose Pen Injector
- RxCUI: 1435115 - 28 ACTUAT teriparatide 0.02 MG/ACTUAT Pen Injector
- RxCUI: 1435115 - teriparatide 0.02 MG/ACTUAT Pen Injector, 28 ACTUAT
- RxCUI: 1435115 - teriparatide 20 MCG/ACTUAT Pen Injector, 28 ACTUAT
- RxCUI: 1435117 - FORTEO 20 MCG/Dose in 28 Dose Pen Injector
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0002 - Eli Lilly And Company
- 0002-9678 - Forteo
- 0002-9678-01 - 1 SYRINGE in 1 CARTON / 2.24 mL in 1 SYRINGE
- 0002-9678 - Forteo
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0002-9678-01 identifies a specific commercial package of 1 syringe in 1 carton / 2.24 ml in 1 syringe of Forteo, a human prescription drug labeled by Eli Lilly And Company. This injection, solution is formulated for subcutaneous use and contains teriparatide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eli Lilly And Company on June 03, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication is not recommended for use in children or young adults whose bones are still growing.
How is this Eli Lilly And Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002967801. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.